Expert Interview
Delving into the phase 2 data on Zealand Pharmaceuticals' Petrelintide, an amylin analog for weight loss and obesity.
Ticker(s): ZEAL, NVO, LLYInstitution: Harvard Medical School
- Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor at Harvard Medical School.
- Manages ~1,000 patients with diabetes and obesity
- Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss.
Roughly how many patients with obesity do you manage?
Added By: max_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for Petrelintide?
Added By: max_adminWhat is your high level view on the potential of long-acting amylin analogs for weight management?
Added By: max_adminAre you convinced that long-acting amylin analogs are more efficaious and/or safer than GLP-1 medications?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
